Apoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients.

T Kuusi(University of Helsinki), Marja‐Riitta Taskinen(University of Helsinki), Hannele Yki‐Järvinen(University of Helsinki), M. Valle(University of Helsinki), Christian Ehnholm(University of Helsinki), Markku S. Nieminen(Cornell University), Esko A. Nikkilä(Research Council of Finland)
Arteriosclerosis An Official Journal of the American Heart Association Inc
March 1, 1989
10.1161/01.atv.9.2.237
Cited by 161

Related Papers

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|5.4k
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
|New England Journal of Medicine|1987|3.9k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
|The Lancet|2003|3.8k
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
|The Lancet|2005|2.9k